When mesenchymal stem cells (MSCs) are administered systemically, the delivery route is not a trivial choice. It determines biodistribution, cell survival, target-tissue engraftment, and ultimately clinical efficacy. Two routes dominate regenerative medicine practice — intravenous (IV) infusion and intrathecal (IT) injection — and they produce profoundly different pharmacokinetic profiles. This article compares them head-to-head, drawing on published preclinical and clinical data, so that clinicians and informed patients can understand the rationale behind route selection.[1][2]

How Intravenous MSC Delivery Works — and Where the Cells Actually Go

Intravenous infusion delivers MSCs directly into the peripheral circulation. From a peripheral vein, the cells travel through the right heart and into the pulmonary capillary bed — and this is where the single most important pharmacokinetic fact about IV MSCs reveals itself. Within minutes of infusion, the vast majority of cells are trapped in the lungs, a phenomenon known as first-pass pulmonary entrapment. Studies using labeled MSCs consistently show that 60–90% of infused cells are retained in the pulmonary microvasculature within the first hour.[3][4]

This entrapment is both a limitation and an advantage. It severely limits the number of cells that reach distant organs — the brain, spinal cord, joints, and kidneys each receive only a small fraction of the infused dose. But pulmonary entrapment also creates a sustained paracrine signaling depot: the trapped MSCs continue secreting anti-inflammatory cytokines, growth factors, and extracellular vesicles for 24–72 hours before clearance. This makes IV delivery well-suited for systemic inflammatory conditions — sepsis, ARDS, graft-versus-host disease, and autoimmune disorders where a broad immunomodulatory signal is the therapeutic goal.[5][6]

Key pharmacokinetic numbers for IV MSCs: ~80% pulmonary first-pass retention within 15 minutes; circulating half-life of 10–30 minutes; detectable paracrine activity for 48–72 hours post-infusion; less than 2% of the injected dose reaches the brain parenchyma.[7]

How Intrathecal MSC Delivery Works — Bypassing the Blood-Brain Barrier

Intrathecal injection places MSCs directly into the cerebrospinal fluid (CSF) via lumbar puncture. This route bypasses the blood-brain barrier (BBB) entirely, delivering cells into the subarachnoid space where they distribute through CSF flow along the spinal cord and into the cerebral ventricles. Because the BBB is the single greatest obstacle to delivering biologics into the central nervous system, IT administration represents a fundamentally different pharmacokinetic strategy than IV infusion.[8]

CSF distribution follows a pressure-gradient flow pattern. MSCs injected into the lumbar cistern travel rostrally — upward — propelled by CSF bulk flow toward the basal cisterns and, over 4–24 hours, into the ventricular system and perivascular spaces. Labeled MSCs have been detected in the brain parenchyma, spinal cord gray matter, and dorsal root ganglia within 6–24 hours of lumbar IT injection in animal models.[9] Cell survival in the CSF compartment is limited — typically 7–14 days — but the paracrine signals they release (BDNF, GDNF, NGF, anti-inflammatory cytokines) persist and exert trophic effects on neurons and glia.

Key pharmacokinetic numbers for IT MSCs: CSF distribution throughout the neuraxis within 4–6 hours; detectable paracrine activity for 7–14 days; direct access to the CNS compartment without BBB limitation; localized delivery means minimal systemic exposure — an advantage for neurological targeting but a limitation for multi-organ conditions.[10]

Head-to-Head: IV vs IT — What the Preclinical Data Shows

Animal studies comparing the two routes consistently show that IT delivery achieves far higher CNS cell concentrations than IV delivery. In rodent models of spinal cord injury, IT-injected MSCs achieved 20–50× higher cell counts in the spinal cord parenchyma compared to IV-injected cells.[11] In models of ischemic stroke, IT delivery produced significantly greater neurological recovery scores than IV delivery at equivalent cell doses, despite the IV group receiving cells earlier post-injury.

However, the picture is not one-sided. IV delivery, despite its low CNS penetration, has shown meaningful efficacy in CNS conditions — not through direct engraftment, but through systemic immunomodulation. In multiple sclerosis models, IV MSCs reduced peripheral T-cell activation and inflammatory cytokine levels, effects that were actually diminished with IT delivery because the cells were sequestered within the CNS compartment and could not interact with peripheral immune organs.[12]

The critical insight: IT delivery excels when the therapeutic target is neural tissue itself — neuroprotection, remyelination, axonal regeneration. IV delivery excels when the goal is systemic immunomodulation — even for neurological conditions with a strong autoimmune component. This is why several clinical programs now use both routes in combination: IV for systemic immune reset, IT for direct neurotrophic support.[13]

IV vs IT: a decision framework. IV is the default for systemic, multi-organ, and inflammatory conditions. IT is indicated when the BBB is the critical barrier and the therapeutic target is neural. Combined IV+IT protocols are emerging for complex neuroinflammatory conditions like MS, ALS, and cerebral palsy, where both systemic and compartmental pathology are present.

Clinical Evidence by Indication

Spinal Cord Injury

IT delivery is the dominant route in SCI clinical trials, and for good reason. Direct CSF administration places cells adjacent to the injury site, and early-phase trials have shown signals of motor and sensory improvement — particularly when MSCs are delivered within weeks to months of injury. A 2023 meta-analysis of 19 clinical studies found that IT MSC delivery in SCI was associated with statistically significant improvements in ASIA motor scores, with a favorable safety profile (no serious adverse events directly attributable to the injection procedure).[14] IV delivery has been explored but shows less consistent neurological benefit.

Neurodegenerative Disease (ALS, MS, Parkinson's)

The evidence is more nuanced here. In ALS, both IV and IT MSC delivery have been tested — IV trials emphasize systemic anti-inflammatory effects (reduced plasma TNF-α, IL-6), while IT trials report modest slowing of functional decline measured by ALSFRS-R.[15] In MS, IV MSCs have the stronger clinical evidence base, with Phase II trials demonstrating reduced gadolinium-enhancing lesions and stabilized EDSS scores — an effect likely mediated by peripheral Treg expansion rather than CNS engraftment. In Parkinson's disease, IT delivery (and the even more targeted intra-striatal route) is favored due to the need for local dopaminergic support.[16]

Orthopedic and Musculoskeletal Conditions

IV delivery is the standard for systemic musculoskeletal conditions. For osteoarthritis, joint pain, and sports injuries, IV MSCs distribute broadly and exert anti-inflammatory effects across multiple joints — a practical advantage over localized intra-articular injections when multiple sites are affected. IT delivery has no role in orthopedic indications; the cells would be sequestered in the CNS with no access to joints, tendons, or bones.

Systemic Inflammatory and Autoimmune Conditions

IV is the unquestioned route for systemic conditions. In graft-versus-host disease, lupus, rheumatoid arthritis, and Crohn's disease, the therapeutic mechanism — broad immunomodulation via pulmonary-trapped MSC secretome — is exactly what IV delivery provides. IT delivery would be counterproductive: it confines cells to the CNS, away from the peripheral immune organs where they need to act.

Safety Considerations — Both Routes, Different Profiles

IV MSC infusion has an established safety record across thousands of patients. The most common adverse events are mild infusion reactions (fever, headache, transient chills) occurring in 3–8% of infusions, typically self-limiting within hours.[17] Pulmonary embolism from cell clumping is a theoretical concern that has not materialized in clinical practice when appropriate cell preparation protocols (filtration, single-cell suspension, controlled infusion rate) are followed.

IT injection carries procedure-specific risks that IV does not. Lumbar puncture itself has a ~5–15% incidence of post-dural puncture headache, which is usually self-limiting but can be severe. More serious complications — spinal hematoma, infection (meningitis), nerve root irritation — are rare (<1 in 1,000) when performed by experienced clinicians under sterile technique.[18] The volume of cell suspension injected intrathecally must be carefully controlled; excessive volume or rapid injection can elevate intracranial pressure.

Safety summary: IV MSCs have the larger safety database and a lower procedure-risk profile. IT MSCs add the risk of lumbar puncture itself — small but real — and require a clinician experienced in intrathecal technique. Both routes have demonstrated acceptable safety in clinical trials when proper protocols are followed.

Practical Considerations — Cost, Convenience, and Patient Experience

IV infusion is logistically simpler. It requires peripheral venous access — a standard nursing procedure — and can be performed in an outpatient infusion suite. Sessions typically last 60–90 minutes including observation. IT injection requires lumbar puncture, which demands a trained clinician, sterile field preparation, and post-procedure observation (typically 1–2 hours lying flat to reduce PDPH risk). The procedure itself takes 15–30 minutes but the total clinic time is longer.

Patient experience differs markedly between the two routes. IV infusion is minimally invasive — a single venipuncture, similar to any IV drip. IT injection involves needle insertion between lumbar vertebrae, which most patients find more anxiety-provoking, though local anesthetic makes it tolerable. Some clinics offer light sedation for IT procedures. Recovery time is also different: IV patients can resume normal activities immediately; IT patients are advised to avoid strenuous activity for 24 hours.

Combination Protocols — When IV + IT Makes Sense

A growing body of clinical practice uses IV and IT MSCs together for complex neurological conditions. The rationale is pharmacokinetically sound: IV MSCs provide systemic immunomodulation (damping peripheral inflammation that drives neuroinflammation), while IT MSCs deliver direct neurotrophic and neuroprotective signals to the CNS compartment. This dual approach has been explored in cerebral palsy, ALS, and traumatic brain injury, with early reports suggesting additive benefit.[13][19]

Combination protocols are more resource-intensive and carry both sets of procedural risks. They should be reserved for conditions where there is a clear dual-compartment rationale — not used as a default. The strongest evidence for combination IV+IT exists in neuroinflammatory and neurodegenerative conditions where both peripheral immune dysregulation and CNS tissue damage are well-documented drivers of pathology.

How VELAR Approaches Route Selection

At VELAR Center, route selection is made individually for each patient based on three factors: the condition being treated, the therapeutic mechanism that matters most, and the patient's clinical history. For systemic autoimmune and inflammatory conditions, IV delivery is our standard. For spinal cord pathology — SCI, compressive myelopathy, spinal muscular atrophy — IT delivery is typically recommended. For complex neurological conditions with both systemic and compartmental components, we discuss combined IV+IT protocols where the evidence supports it.

Every IT procedure at VELAR is performed by a physician experienced in lumbar puncture technique, under sterile conditions, with ultrasound guidance where indicated. Every IV infusion uses freshly thawed, viability-verified MSCs prepared in single-cell suspension and infused over 30–45 minutes — the protocol that has demonstrated the lowest incidence of infusion reactions in published series.[17]

Frequently Asked Questions

Which route is better — IV or intrathecal?

Neither is universally better; each is optimal for different clinical scenarios. IV is preferred for systemic inflammatory and multi-organ conditions. Intrathecal is preferred when the therapeutic target is the central nervous system and the blood-brain barrier must be bypassed. The right choice depends entirely on what is being treated.

Can I have both IV and intrathecal MSCs in the same treatment session?

Yes, combined IV+IT protocols are used for complex neurological conditions where both systemic immunomodulation and direct CNS support are desired. This approach is more resource-intensive and carries both sets of procedural risks but may offer additive benefit for select indications like ALS and cerebral palsy.

How painful is an intrathecal injection?

Local anesthetic is used at the injection site, and most patients describe the procedure as pressure rather than pain. Some discomfort during needle placement is normal. The most common post-procedure issue is a positional headache (post-dural puncture headache), which resolves with rest and hydration in most cases.

How long do the cells stay active after IV vs IT delivery?

After IV infusion, MSCs are largely cleared from circulation within hours but continue secreting paracrine factors for 48–72 hours from the pulmonary depot. After IT injection, paracrine activity is detectable in the CSF for 7–14 days. The therapeutic window — the period during which biologically meaningful signals are being sent — is longer with IT delivery for CNS targets.

Is IT delivery safe for children?

Lumbar puncture in children requires pediatric-specific expertise, but the procedure itself has been performed safely for decades (it is the standard route for intrathecal chemotherapy in pediatric oncology). MSC IT delivery in children has been studied most extensively in cerebral palsy trials, with acceptable safety profiles reported.

Does insurance cover intrathecal MSC therapy?

MSC therapy — regardless of delivery route — is generally not covered by standard health insurance plans as it remains investigational for most indications. Patients should confirm coverage directly with their insurer. VELAR provides transparent cost breakdowns during consultation.

Limitations and Realistic Expectations

MSC therapy by any route remains an investigational treatment for most indications. The pharmacokinetic data reviewed here comes predominantly from preclinical models and early-phase clinical trials; large-scale randomized controlled trials comparing IV and IT delivery head-to-head for specific conditions are limited.[20] Individual patient responses vary significantly, and no route of administration can guarantee a specific clinical outcome. This article is intended for educational purposes and does not constitute medical advice. Any decision about MSC therapy — including route selection — should be made in consultation with a qualified physician who has reviewed your full medical history.

References

  1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. doi:10.1126/science.284.5411.143 ↩
  2. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  3. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells and Development. 2009;18(5):683-692. doi:10.1089/scd.2008.0253 ↩
  4. Kurtz A. Mesenchymal stem cell delivery routes and fate. International Journal of Stem Cells. 2008;1(1):1-7. doi:10.15283/ijsc.2008.1.1.1 ↩
  5. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63. doi:10.1016/j.stem.2009.05.003 ↩
  6. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  7. Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: the lung barrier. Transplantation Proceedings. 2007;39(2):573-576. doi:10.1016/j.transproceed.2006.12.019 ↩
  8. Bakshi A, Hunter C, Swanger S, et al. Minimally invasive delivery of stem cells for spinal cord injury: advantages of the lumbar puncture technique. Journal of Neurosurgery: Spine. 2004;1(3):330-337. doi:10.3171/spi.2004.1.3.0330 ↩
  9. Paul C, Samdani AF, Betz RR, et al. Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods. Spine. 2009;34(4):328-334. doi:10.1097/BRS.0b013e31819403ce ↩
  10. Shin DA, Kim JM, Kim HI, et al. Comparison of intrathecal and intravenous administration of human mesenchymal stem cells in a rat model of spinal cord injury. Spine. 2013;38(15):E915-E922. doi:10.1097/BRS.0b013e318296fc1e ↩
  11. Syková E, Jendelová P, Urdzíková L, et al. Bone marrow stem cells and polymer hydrogels — two strategies for spinal cord injury repair. Cellular and Molecular Neurobiology. 2006;26(7-8):1113-1129. doi:10.1007/s10571-006-9007-2 ↩
  12. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755-1761. doi:10.1182/blood-2005-04-1496 ↩
  13. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology. 2010;67(10):1187-1194. doi:10.1001/archneurol.2010.248 ↩
  14. Zhao T, Yan W, Sun P, et al. Intrathecal transplantation of mesenchymal stem cells for spinal cord injury: a systematic review and meta-analysis. Stem Cell Research & Therapy. 2023;14:88. doi:10.1186/s13287-023-03309-4 ↩
  15. Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis. JAMA Neurology. 2016;73(3):337-344. doi:10.1001/jamaneurol.2015.4321 ↩
  16. Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Translational Research. 2010;155(2):62-70. doi:10.1016/j.trsl.2009.07.006 ↩
  17. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  18. Evans RW, Armon C, Frohman EM, Goodin DS. Assessment: prevention of post-lumbar puncture headaches. Neurology. 2000;55(7):909-914. doi:10.1212/WNL.55.7.909 ↩
  19. Rah WJ, Lee YH, Moon JH, et al. Neuroregenerative potential of intravenous and intrathecal mesenchymal stem cells in neonatal hypoxic-ischemic brain injury. Stem Cells Translational Medicine. 2017;6(11):1951-1962. doi:10.1002/sctm.17-0034 ↩
  20. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩